FOLH1 and cancer: This Phase 2 trial of targeted radioligand therapy aimed to assess the effect of 177Lu-PSMA-617 in patients with advanced mCRPC for the first time in Japan, mirroring clinical practice conditions in Japan, in the absence of potential cofounding effects of any new anti-cancer treatment therapies.